For its 2024 fiscal year, ACELYRIN INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Shao-Lee Lin M.D., Ph.D.
Founder, Chief Executive Officer and Director
Total Compensation $9,427,551 View details Pay Rank By Title In Biotechnology industry #122 View more
Melanie Gloria
Chief Operating Officer
Total Compensation $4,760,350 View details Pay Rank By Title In Biotechnology industry #26 View more
Martin Babler
President, Chief Executive Officer and Director
Total Compensation $10,661,219 View details Pay Rank By Title In Biotechnology industry #98 View more
Roy Hardiman
Chief Business and Strategy Officer
Total Compensation $3,216,673 View details Pay Rank By Title In Biotechnology industry #75 View more
David Goldstein Ph.D.
Chief Scientific Officer
Total Compensation $3,244,462 View details Pay Rank By Title In Biotechnology industry #19 View more
Gil Labrucherie
Chief Financial Officer & Chief Business Officer
Total Compensation $6,538,637 View details Pay Rank By Title In Biotechnology industry #32 View more
Shephard Mpofu
Chief Medical Officer
Total Compensation $2,529,667 View details Pay Rank By Title In Biotechnology industry #112 View more
Mina Kim
Chief Executive Officer
Total Compensation $5,659,331 View details Pay Rank By Title In Biotechnology industry #227 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at ACELYRIN INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. ACELYRIN INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. ACELYRIN INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Shao-Lee Lin M.D., Ph.D.
Founder, Chief Executive Officer and Director
Total Cash $378,561 Equity $8,024,393 Other $1,024,597 $9,427,551
Melanie Gloria
Chief Operating Officer
Total Cash $619,271 Equity $3,611,168 Other $529,911 $4,760,350
Martin Babler
President, Chief Executive Officer and Director
Total Cash $912,638 Equity $9,748,581 Other $0 $10,661,219
Roy Hardiman
Chief Business and Strategy Officer
Total Cash $619,841 Equity $2,596,832 Other $0 $3,216,673
David Goldstein Ph.D.
Chief Scientific Officer
Total Cash $651,368 Equity $2,593,094 Other $0 $3,244,462
Gil Labrucherie
Chief Financial Officer & Chief Business Officer
Total Cash $512,500 Equity $6,021,882 Other $4,255 $6,538,637
Shephard Mpofu
Chief Medical Officer
Total Cash $675,796 Equity $1,850,022 Other $3,849 $2,529,667
Mina Kim
Chief Executive Officer
Total Cash $898,050 Equity $4,752,691 Other $8,590 $5,659,331
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.